For the year ending 2025-12-31, SNSE had -$1,326K decrease in cash & cash equivalents over the period. -$20,469K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -21,085 |
| Stock-based compensation expense | 1,274 |
| Depreciation and amortization | 122 |
| Accretion on marketable securities | -699 |
| Impairment of financing right-of-use asset assets | 0 |
| Impairment of equipment | 0 |
| Non-cash lease expense | 1,510 |
| Amortization of financing lease right-of-use assets | 17 |
| Prepaid expenses | -243 |
| Other assets | -80 |
| Accounts payable and accrued liabilities | 233 |
| Compensation and employee benefits | -562 |
| Operating lease liabilities | -1,586 |
| Other liabilities | 0 |
| Net cash used in operating activities | -20,453 |
| Purchases of property and equipment | 16 |
| Purchases of short-term investments | 25,155 |
| Maturities of short-term investments | 44,693 |
| Proceeds from sale of property and equipment | 250 |
| Net cash provided by investing activities | 19,772 |
| Principal payments for financing leases | 790 |
| Proceeds from the sale of financing lease assets | 142 |
| Payment of employee restricted stock tax withholdings | 3 |
| Employee stock purchase plan proceeds | 5 |
| Cash in lieu of fractional shares for reverse stock split | 1 |
| Exercise of options into common stock | 2 |
| Net cash used in financing activities | -645 |
| Net decrease in cash and cash equivalents | -1,326 |
| Cash and cash equivalents at beginning of period | 9,994 |
| Cash and cash equivalents at end of period | 8,668 |
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)